Suppr超能文献

在中国第一个黏多糖贮积症 III 型(Sanfilippo C 综合征)家系中鉴定和表征新型遗传变异。

Identification and characterization of novel genetic variants in the first Chinese family of mucopolysaccharidosis IIIC (Sanfilippo C syndrome).

机构信息

Department of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, China.

Provincial Clinical Research Center for Rheumatic and Immunologic Diseases, Xiangya Hospital, Central South University, Changsha, China.

出版信息

J Cell Mol Med. 2024 Apr;28(8):e18307. doi: 10.1111/jcmm.18307.

Abstract

Mucopolysaccharidosis type IIIC (MPS IIIC) is one of inherited lysosomal storage disorders, caused by deficiencies in lysosomal hydrolases degrading acidic mucopolysaccharides. The gene responsible for MPS IIIC is HGSNAT, which encodes an enzyme that catalyses the acetylation of the terminal glucosamine residues of heparan sulfate. So far, few studies have focused on the genetic landscape of MPS IIIC in China, where IIIA and IIIB were the major subtypes. In this study, we utilized whole-exome sequencing (WES) to identify novel compound heterozygous variants in the HGSNAT gene from a Chinese patient with typical MPS IIIC symptoms: c.743G>A; p.Gly248Glu and c.1030C>T; p.Arg344Cys. We performed in silico analysis and experimental validation, which confirmed the deleterious pathogenic nature of both variants, as evidenced by the loss of HGSNAT activity and failure of lysosomal localization. To the best of our knowledge, the MPS IIIC is first confirmed by clinical, biochemical and molecular genetic findings in China. Our study thus expands the spectrum of MPS IIIC pathogenic variants, which is of importance to dissect the pathogenesis and to carry out clinical diagnosis of MPS IIIC. Moreover, this study helps to depict the natural history of Chinese MPS IIIC populations.

摘要

黏多糖贮积症 III 型(MPS III)是一种遗传性溶酶体贮积症,由溶酶体水解酶降解酸性黏多糖的缺陷引起。导致 MPS III 的基因是 HGSNAT,它编码一种酶,可催化硫酸乙酰肝素末端葡萄糖胺残基的乙酰化。到目前为止,很少有研究关注中国 MPS III 的遗传景观,其中 IIIA 和 IIIB 是主要亚型。在这项研究中,我们利用外显子组测序(WES)从一名具有典型 MPS III 症状的中国患者中鉴定出 HGSNAT 基因的新型复合杂合变异:c.743G>A;p.Gly248Glu 和 c.1030C>T;p.Arg344Cys。我们进行了计算机分析和实验验证,证实了这两种变异均具有有害的致病性,这表现在 HGSNAT 活性丧失和溶酶体定位失败。据我们所知,MPS III 是中国首次通过临床、生化和分子遗传学发现来确认的。因此,我们的研究扩展了 MPS III 致病性变异的范围,这对于剖析发病机制和进行 MPS III 的临床诊断具有重要意义。此外,这项研究有助于描绘中国 MPS III 人群的自然史。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c93f/11015392/a5f14f9b72eb/JCMM-28-e18307-g002.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验